Module 3: Initiating Long-Term HAE Prophylaxis

Launch Date:
January 27, 2023
Return to Enrollment Page

Primary Audience:

This activity is intended to meet the educational needs of healthcare professionals involved in the care of patients with hereditary angioedema.

OVERVIEW

This module will discuss the factors that go into the shared decision making process when deciding to initiate prophylaxis against hereditary angioedema.

FACULTY

Corinne Savides Happel, MD

Assistant Professor of Medicine 
Allergy and Immunology 
Johns Hopkins Hospital
Baltimore, MD

Dr. Corinne Happel is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her area of clinical expertise is allergy immunology. 

Dr. Happel earned her M.D. from the University of Virginia School of Medicine. She completed her residency at the Dartmouth-Hitchcock Medical Center and performed a fellowship in allergy and clinical immunology at the National Institutes of Health.

Marc Riedl, MD

Allergist/Immunologist
Clinical Director, Angioedema Center
Professor of Medicine
UC San Diego Health
San Diego, CA

Marc A. Riedl, MD, is a board-certified allergist/immunologist who specializes in diagnosing and treating angioedema, immune deficiency diseases, asthma, anaphylaxis, food and medication sensitivity, and other related conditions. Dr. Riedl is the clinical director of UC San Diego Health's U.S. HAEA Angioedema Center, which offers comprehensive evaluations and treatment options for people with all forms of angioedema.
 
An international thought leader on angioedema, Dr. Riedl is a member of the U.S. Hereditary Angioedema Association's Medical Advisory Board and has been a driving force behind hereditary angioedema research. He is extensively published, and his work has appeared in The New England Journal of Medicine, JAMA, Allergy, and Asthma and Immunology, among others.
 
As a professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Riedl mentors and instructs medical students, residents and fellows. He serves as the training program director for Allergy and Immunology Fellowship Program. Dr. Riedl is also involved in numerous clinical research trials that study novel therapeutics to prevent and treat hereditary angioedema attacks. He lectures frequently at both national and international medical conferences. He serves on the editorial board for Clinical Immunology and the Journal of Asthma, and is a reviewer for many medical journals.
 
Dr. Riedl completed a fellowship in clinical immunology and allergy at UCLA School of Medicine and a residency in internal medicine at Barnes-Jewish Hospital of Washington University School of Medicine in St. Louis. He earned his medical degree from University of Chicago Pritzker School of Medicine. Dr. Riedl is board-certified in allergy and immunology and clinical pharmacology.
 
He is a member of numerous professional organizations, including the American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma & Immunology, and the Clinical Immunology Society. Dr. Riedl has also served on the Special Emphasis Grant Review Committee for National Institutes of Health (NIH)-National Institute of Environmental Health Sciences (NIEHS), and as an appointed consultant for the U.S. Food and Drug Administration's Advisory Committee.

LEARNING OBJECTIVES

1.
Apply expert recommendations in evaluating important factors for the consideration and initiation of long-term prophylaxis in HAE.